AN2 Therapeutics, Inc.: director Marks Gilbert Lynn received 2,283 shares

What happened Marks Gilbert Lynn, a director of AN2 Therapeutics, Inc., received 2,283 shares (transaction code A) on Oct 12, 2026. The filing reports a price of $0.00 per share and a total value of $0.

Key details

• Transaction date and price: Oct 12, 2026; acquisition (A); $0.00 per share; total $0.
• Shares owned after the transaction: the filing does not report shares owned following the transaction.
• Footnote: "Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately." (F1)
• Filing date and timeliness: Form 4 filed Oct 13, 2026; the filing does not indicate it was late.

Why it may matter

• This was an award (A) of shares issued in lieu of cash compensation and vested immediately; it is not a market purchase or sale.
• A filing does not show why the insider traded or why the company acted.